Radioimmunotherapy: current state of the problem
Vol. 62 No. 1 (2016), Articles
Vol. 62 No. 1 (2016)

Radioimmunotherapy: current state of the problem

Articles
https://doi.org/10.37469/0507-3758-2016-62-1-24-30
Published 15.12.2016
Tomsk Research Institute of Oncology; National Research Tomsk Polytechnic University
National Research Tomsk Polytechnic University
Tomsk Research Institute of Oncology; National Research Tomsk Polytechnic University
Tomsk Research Institute of Oncology; National Research Tomsk Polytechnic University
Tomsk Research Institute of Oncology; National Research Tomsk Polytechnic University

Abstract

This review presents modern data about one of the promising direction in treatment of malignancies, which is called radioimmunotherapy. The special attention is paid to search of new targets and development of radiopharmaceuticals that will allow improving quality and accuracy of the directed impact on tumors of various localizations.
https://doi.org/10.37469/0507-3758-2016-62-1-24-30
PDF (Русский)

References

Бахлушев В.П., Павлов К.А., Чехонин В.П. Моноклональные антитела в диагностике низкодифференцированных лимфом //Биомедицинская химия. - 2009. - № 2. - С. 140-154.

Деев С.М., Лебеденко Е.Н. Современные технологии создания неприродных антител для клинического применения //Acta Naturae. - 2009. - C. 32-50.

Имянитов Е.Н. Молекулярная диагностика в онкологии // Вопр. онкол. 2012. - Т 58. - № 2. - С. 153-163.

Покровский В.С., Лесная Н.А., Трещалина Е.М., и пр. Перспективы разработки новых ферментных противоопухолевых препаратов// Вопр. онкол. - 2011. - Т. 57. - № 2. - С. 155-164.

Полянский О.Л., Лебеденко Е.Н., Деев С.М. ERBB онкогены - мишени моноклональных антител // Биохимия. - 2012. - №77 (3). - С. 289-311.

Практические рекомендации по лекарственному лечению злокачественных опухолей Российского общества клинической онкологии, 2014.

Семиглазов В.Ф. Новые подходы в лечении рака молочной железы // Вопр. онкол. - 2013. - Т. 59. - № 3. - С. 288-291.

Чиссов В. И., Дарьялова С.Л. Клинические рекомендации. Онкология. - Издательство: ГЭОТАР-Медиа, - 2009. - С. 960.

Abbas N., Heyerdahl H., Bruland О. S. et.al. Experimental a-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab // EJNMMI Research. - 2011. - № 1. - P 1-12.

Agulnik M. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN) // Med. Oncol. - Vol. 29. - Р 2481-2491.

Boerman O. C., van Schaijk F. G., Oyen W. J.G., et.al. Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step // J. Nucl. Med. - 2003. - Vol. 44 (3). - Р 400 - 411.

Boudousq V., Ricaud S., Garambois V. et al. Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies // J. Nucl. Med. - 2010. - Vol. 51 (11). - Р 1748-1755.

Chen K.T., Lee T.W., Lo J.M. In vivo examination of (188) Re(I)-tricarbonyl- labeled trastuzumab to target HER2-overexpressing breast cancer // Nucl. Med. Biol. - 2009. - Vol. 36 (4). - P. 355-361.

Dewaraja Y.K., Schipper M.J., Roberson P.L. et al. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results usin g3-dimensional dosimetry including radiobiologic modeling // J. Nucl. Med. - 2010. - Vol. 51 (7). - P. 1155-1162.

Farrokhi S., Ravanbod M. R., Amiri S. et.al. Radioimmunotherapy-based treatment of cancer // Iran J. Nucl. Med. - 2012. - Vol. 20 (1). - С.45-53.

Goldsmith S. J. Radioimmunotherapy of lymphoma: bexxar and zevalin // Seminars in Nuclear Medicine. - 2010. - Vol. 40 (2). - Р 122-135.

Hei T.K., Zhou H., Chai Y, Ponnaiya B., Ivanov V.N. Radiation induced non- targeted response: mechanism and potential clinical implications // Curr. Mol. Pharmacol. - 2011. - Vol. 4 (2). - P 96-105.

Heskamp S, Boerman OC, Molkenboer-Kuenen JD et al. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies // Int. J. Cancer. - 2013. - Vol. 133 (2). - Р. 307-314.

Huang P., Buchanan J.W., Kawashima H. Radioimmunotherapy: A Specific Treatment Protocol for Cancer by Cytotoxic Radioisotopes Conjugated to Antibodies // The Scientific World Journal. - 2014. - P. 1-10.

Jain M., Gupta S., Kaur S. Emerging Trends for Radioimmunotherapy in Solid Tumors // Cancer biotherapy and radiopharmatheticals. - 2013. - Vol. 28. - P. 639650.

Kawashima H. Radioimmunotherapy: A Specific Treatment Protocol for Cancer by Cytotoxic Radioisotopes Conjugated to Antibodies // The Scientific World Journal. - 2014. - Vol. 14. - С. 1-10.

Kinuya S., Yokoyama K., Koshida K. et al. Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy // Eur. J. Nucl. Med. Mol. Imaging. - 2004. - Vol. 31. - Р 981-985.

Kitson S. L., Cuccurullo V., Moody T. S., Mans L. Radionuclide antibody-conjugates, a targeted therapy towards cancer // Current Radiopharmaceuticals. - 2013. - Vol. 6 (2). - P 57-71.

Kraeber-Bodere F., Bodet-Milin C., Niaudet C. et al. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigenexpressing medullary thyroid cancer xenograft // J. Nucl. Med. - 2010. - Vol. 51. - Р624-631.

Kohler G., Milstein C. Continious culture of fused cells secreting antibody of predefined specificity // Nature. - 1975. - Vol. 256. - P. 495-497.

Lane D.M., Eagle K.F., Begent R.H. et al. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab)2 antibodies // Br. J. Cancer. - 1994. - Vol. 70 (3). - P. 521-525.

Leahy M. F., Turner J. H. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients // Blood. - 2011. -Vol. 117 (1). - Р 45-52.

Liersch T., Meller J., Bittrich M. et al. Update of carcinoembryonic antigen radioimmunotherapy with (131) I-labetuzumab after salvage resection of colorectal liver metastases: Comparison of outcome to a contempora neous control group // Ann. Surg. Oncol. - 2007. - Vol. 14. - P 2577.

Lin F.I., Iagaru A. Current concepts and future directions in radioimmunotherapy // Cur. Drug Discov. Technol. - 2010. - Vol. 7 (4). - Р. 253-262.

Maleki L. A., Baradaran B., Majidi J. Future prospects of monoclonal antibodies as magic bullets in immunotherapy // Human Antibodies. - 2013. - Vol. 22 (1-2). - Р. 9-13.

Meredith RF, Buchsbaum DJ, Alvarez RD. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer // Clin. Cancer Res. - 2007. - Vol. 13. - P. 5643.

Navarro-Teulon I., Lozza C., Pèlegrin A. et.al. General overview of radioimmunotherapy of solid tumors // Immunotherapy. - 2013. - Vol. 5 (5). -.467-487.

Pastuskovas CV, Mundo EE, Williams SP et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model // Mol.Cancer Ther. - 2012. - Vol. 11 (3). - Р. 752-762.

Pouget J.-P, Lozza1 C., Deshayes E., Boudousq V. et al. Introduction to radiobiology of targeted radionuclide therapy // Frontiers in medicine. - 2015. - Vol. 2. - P. 1-11.

Pouget J.P, Navarro-Teulon I., Bardiès M. et.al. Clinical radioimmunotherapy - the role of radiobiology // Nat. Rev. Clin. Oncol. - 2011. - Vol. 8. - (12). -.720734.

Rades D., Nadrowitz R., Buchmann I. et.al. Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC) // Strahlenther. Onkol. - 2010. - Vol. 186. - Р. 458-462.

Rajkumar V., Dearling J.L., Packard A. et al. Radioimmunotherapy: Optimizing delivery to solid tumors // Ther. Deliv. - 2011. - Vol. 2 (5). - Р 567- 572.

Rasaneh S., Rajabi H., Babaei M.H. et. al. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer // Nucl. Med Biol. - 2010. - Vol. 37 (8). - P 949-955.

Salaun P.Y, Bodet-Milin C., Frampas E. et. al. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma // Cancer. - 2010. - Vol. 116. - Р 1053-1058.

Sharkey R.M., Goldenberg D.M. Cancer radioimmunotherapy // Immunotherapy. - 2011. - Vol. 3 (3). - Р 349-370.

Sihver W., Pietzsch J., Krause M. et.al. Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy // Pharmaceuticals. - 2014. - Vol. 7. - Р. 311-338.

Song H., Hobbs R.F., Vajravelu R. et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: Comparing efficacy with 213Bi and 90Y // Cancer Res. - 2009. - Vol. 69 (23). - P. 8941-8948.

Song H., Shahverdi K., Huso D.L. et al. 213Bi (alpha-emitter) - antibody targeting of breast cancer metas-tases in the neu-N transgenic mouse model // Cancer Res.- 2008. - Vol. 68 (10). - Р3873-3880.

Tomblyn M.B., Katin M.J., Wallner PE. The New Golden Era for Radioimmunotherapy: Not Just for Lymphomas Anymor e // Cancer Control. - 2013. - Vol. 20. - P. 60-71.

Wahl R.L. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists // J. Nucl. Med. - 2011. - Vol. 52 (5). - P. 830-838.

Wang C.K. The progress of radiobiological models in modern radiotherapy with emphasis on the uncertain tissue // Mutat. Res. - 2010. - Vol. 704 (1-3). - P. 175-181.

Wheeler R.H., Meredith R.F., Saleh M.N. et. al. A phase II trial of IL-1+ radioimmunotherapy (RIT) in patients with metastatic colon cancer // The Oncologist. -1996. - Vol. 1. - Р 190-200.

Wilken J.A., Maihle N.J. Primary trastuzumab resistance: new tricks for an old drug // Ann. NY Acad. Sci. - 2010. - Vol. 1210. - Р53-65.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...